US5415874A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Natural killer cell lines and clones with antigen specificity
Assignee: Leland Stanford Junior University
•
Filing: 1989-10-31
•
Granted: 1995-05-16
•
Expires: 2009-10-31
Abstract
Abstract Lymphocytes of NK phenotype were cultured with stimulator cell lines in the presence of growth factor containing medium. The resulting lines and clones derived from these lines expressed CD16 and/or Leu 19, but lacked detectable CD3 or T cell receptor gamma / delta complexes on the cell surface. In addition to displaying potent cytolytic activity against K562 erythroleukemia cells (a classical NK target), the vast majority of these lines and clones lysed their specific stimulator cell lines to a significantly greater extent than irrelevant cell lines. These results indicate that some CD3- lymphocytes, phenotypically indistinguishable from NK cells, can recognize and lyse allogeneic targets in a specific manner.
Inventors
- 👤 Jeffrey R. Bender
- 👤 Ruggero Pardi
- 👤 Edgar G. Engleman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:46
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0634; C12N5/0646; A; A61; A61K; A61K39/00; A61K2039/51; A61K2039/515; A61K2039/5158
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
78 words
A method of preparing natural killer cells, comprising obtaining a partially purified preparation of natural killer cells, contacting said preparation with a selected target cell type, selecting natural killer cells based on their adhesion to the selected target cell type, and culturing the selected natural killer cells by providing an agent which promotes proliferation of the selected natural killer cells, where the proliferated NK cells demonstrate preferential cytotoxicity against the target cell type to which they originally adhered.
Claim 2
Independent Claim
78 words
A method of preparing natural killer cells, comprising obtaining a partially purified preparation of natural killer cells, contacting said preparation with a selected target cell type, selecting natural killer cells based on their adhesion to the selected target cell type, and culturing the selected natural killer cells by providing an agent which promotes proliferation of the selected natural killer cells, where the proliferated NK cells demonstrate preferential cytotoxicity against the target cell type to which they originally adhered.
Claim 3
Dependent Claim
20 words
The method of claim 1, where said partial purification includes removing the monocytes, B-cells, CD3 + and CD5 + cells.
Claim 4
Dependent Claim
34 words
The method of claim 2, where said removing includes passing the peripheral blood lymphocytes over nylon wool columns followed by incubation of the remaining lymphocytes in the presence of anti-CD3 and anti-CD5 monoclonal antibodies.
Claim 5
Dependent Claim
28 words
The method of claim 3, wherein the partially purified natural killer cells are less than about 0.5% CD3 + cells and greater than about 85% CD16 + cells.
Claim 6
Dependent Claim
28 words
The method of claim 3, wherein the partially purified natural killer cells are less than about 0.5% CD3 + cells and greater than about 85% leu19 + cells.
Claim 7
Dependent Claim
43 words
The method of claim 1, wherein said contacting includes incubating the partially purified natural killer cells in the presence of a monolayer of the selected target cell type and washing away the natural killer cells that have not adhered to the target cells.
Claim 8
Dependent Claim
25 words
The method of claim 1, wherein said culturing of the enriched natural killer cells is performed with the addition of interleukin-2 to the culture medium.
Claim 9
Dependent Claim
80 words
A preparation of natural killer cells prepared essentially as follows: obtaining a partially purified preparation of natural killer cells, contacting said preparation with a selected target cell type, selecting natural killer cells based on their adhesion to the selected target cell type, and culturing the selected natural killer cells by providing an agent which promotes proliferation of the selected natural killer cells, where the proliferated NK cells demonstrate preferential cytotoxicity against the target cell type to which they originally adhered.
Claim 10
Dependent Claim
80 words
A preparation of natural killer cells prepared essentially as follows: obtaining a partially purified preparation of natural killer cells, contacting said preparation with a selected target cell type, selecting natural killer cells based on their adhesion to the selected target cell type, and culturing the selected natural killer cells by providing an agent which promotes proliferation of the selected natural killer cells, where the proliferated NK cells demonstrate preferential cytotoxicity against the target cell type to which they originally adhered.
Claim 11
Dependent Claim
22 words
The preparation of claim 8 which contains less than about 0.5% CD3 + cells and greater than about 85% CD16 + cells.
Claim 12
Dependent Claim
22 words
The preparation of claim 8 which contains less than about 0.5% CD3 + cells and greater than about 85% leu19 + cells.
Claim 13
Dependent Claim
20 words
The preparation of claim 8, wherein the selected target cell type is either microvascular endothelium or a lymphoblastoid cell line.
Claim 14
Dependent Claim
23 words
The preparation of claim 8, wherein the selected target cell type is selected from the group consisting of tumor cells and virus-infected cells.
Claim 15
Dependent Claim
43 words
The preparation of claim 8, wherein said contacting includes incubating the partially purified natural killer cells in the presence of a monolayer of the selected target cell type and washing away the natural killer cells that have not adhered to the target cells.
Claim 16
Dependent Claim
25 words
The preparation of claim 8, wherein said culturing of the enriched natural killer cells is performed with the addition of interleukin-2 to the culture medium.
References Cited (Backward Citations)
US5028424A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-05-15 | 1998-11-14 | 1999-05-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-05-15 | 2002-11-14 | 2003-05-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-05-15 | 2006-11-14 | 2007-05-16 | $7700.00 | Window Closed / Lapsed |